Skip to main content
. 2017 Jan 17;28(5):1603–1613. doi: 10.1681/ASN.2016030343

Figure 3.

Figure 3.

Complement activation biomarker assessments. Plasma levels of (A) C3, (B) Bb, and (C) sC5b9 of 15 anti-C3b/anti-FB–positive plasma samples and 30 healthy controls. *P<0.05; **P>0.01; ***P>0.001. Ctr, control cohort of C3G without anti-C3b and anti-FB autoantibodies; HD, healthy donor.